D&D Pharmatech (XKRX:347850) 5-Year EBITDA Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech 5-Year EBITDA Growth Rate?

D&D Pharmatech's EBITDA per Share for the three months ended in Sep. 2024 was ₩-642.61.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of D&D Pharmatech was -0.10% per year. The lowest was -0.10% per year. And the median was -0.10% per year.

Competitive Comparison of D&D Pharmatech's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, D&D Pharmatech's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

D&D Pharmatech's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D&D Pharmatech's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where D&D Pharmatech's 5-Year EBITDA Growth Rate falls into.

D&D Pharmatech 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

D&D Pharmatech (XKRX:347850) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

D&D Pharmatech 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR

Website

http://www.ddpharmatech.com

D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech Headlines

No Headlines